Global Flu Influenza Vaccine Market 2025-2035

Flu Influenza Vaccine Market Size, Share & Trends Analysis Report by Vaccine Type (Quadrivalent, and Trivalent), by Technology (Egg-Based, and Cell Culture), by Age Group (Pediatric, and Adult), and by Route of Administration (Injection, and Nasal Spray) Forecast Period (2025-2035)

Industry Overview

Flu influenza vaccine market was valued at $8.4 billion in 2024 and is projected to reach $16.3 billion by 2035, growing at a CAGR of 6.6% during the forecast period (2025–2035). Flu influenza vaccine market is primarily driven by increasing demand for more effective flu vaccines, supported by the adoption of next-generation platforms such as mRNA-based formulations. For instance, in June 2025, Moderna announced positive Phase 3 results for its seasonal flu vaccine, mRNA-1010, demonstrating a 26.6% higher relative vaccine efficacy (rVE) compared with a licensed standard-dose vaccine in adults older than 50 years. The vaccine showed strong efficacy across all influenza strains, such as A/H1N1, A/H3N2, and B/Victoria, with consistent performance across age groups, risk profiles, and vaccination histories. Notably, in individuals aged 65 and above, mRNA-1010 achieved an rVE of 27.4%.

Market Dynamics

Rising Global Disease Burden

The global influenza pandemic has increased the demand for vaccinations, propelling market growth because of the significant health risks associated with the disease. According to the World Health Organization (WHO), in February 2025, seasonal influenza infects nearly one billion people annually globally, with 3–5 million cases resulting in severe illness. It causes between 290,000 and 650,000 respiratory-related deaths each year. In developing countries, 99% of influenza-associated lower respiratory tract infection deaths among children occur in those under five years of age. Symptoms generally appear 1–4 days after infection and last for about a week, including fever, cough, sore throat, body aches, and fatigue. While treatment primarily focuses on symptomatic relief and most patients recover within a week.

Tech Innovations Boost Global Flu Influenza Vaccine Market Growth

Innovations in vaccine design, cell-based manufacturing, and recombinant technologies are boosting vaccine efficacy and expanding immunization coverage. These advancements enable faster development, improved strain targeting, and decreased production risks are key factors driving global flu influenza vaccine market growth. For instance, in February 2025, Zydus launched VaxiFlu-4, India’s first quadrivalent flu vaccine offering protection against four virus strains. Developed at the company’s Vaccine Technology Centre in Ahmedabad, the vaccine is certified by the Central Drug Laboratory (CDL) and aligns with the WHO-recommended composition. With its enhanced immunity-boosting formulation, VaxiFlu-4 is poised to help prevent flu outbreaks and decrease the risk of strain mismatches.

Market Segmentation

• Based on the vaccine type, the market is segmented into quadrivalent and trivalent.
• Based on the technology, the market is segmented into egg-based and cell culture.
• Based on the age group, the market is segmented into pediatric and adult.
• Based on the route of administration, the market is segmented into injection and nasal spray.

Egg-Based: A Key Segment in Market Growth

The growth in the market is primarily driven by the development of quadrivalent and high-dose vaccines that provide extended strain protection and increased protection, primarily among immunocompromised and older adults. For instance, in October 2024, Sanofi introduced an egg-based high-dose quadrivalent influenza vaccine (QIV-HD) in UK adults aged 65+ and clinically at-risk adults aged 60 to 64 years. QIV-HD has been recommended by the Joint Committee on Vaccination and Immunization (JCVI) and is funded by the NHS. The vaccine has a higher antigen content to give extra protection to older individuals at greater risk of severe flu complications. The superior protective efficacy of high-dose versus standard-dose influenza in the elderly is supported by more than a decade of evidence from both clinical trials and real-world settings.

Regional Outlook

The global flu influenza vaccine market is further divided by region, including North America (the US and Canada), Europe (the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific), and the Rest of the World (the Middle East & Africa, and Latin America).

Government Support & Funding in Asia-Pacific

Indian governments are investing increasingly to increase flu vaccination levels, combined with enhanced budgetary expenditure, which is driving market growth. For instance, in March 2023, Maharashtra's health department invested another ₹70 lakh in districts to buy influenza vaccines in reaction to growing instances of H1N1 and H3N2, with 417 cases of H1N1 and close to 250 cases of H3N2 reported to date this year, including a couple of deaths. Free flu vaccination 2015 has been provided to high-risk individuals, pregnant women, and health workers.

North America Maintains Strong Market Position

North America holds a significant market share, driven by the rising demand for flu vaccines due to repeated seasonal outbreaks that have major health consequences. According to the Centers for Disease Control and Prevention (CDC), reported in February 2025 that the US saw about 24 million cases of influenza, 310,000 hospitalizations, and 13,000 fatalities during the current 2024–2025 flu season.

The major companies operating in the global flu influenza vaccine market include AstraZeneca plc, CSL Seqirus Inc., GSK plc, Moderna, Inc., and Sanofi, among others. Market players are leveraging partnerships, collaborations, mergers, and acquisition strategies for business expansion and innovative product development to maintain their market positioning.

Recent Developments

• In July 2025, Sanofi acquired London‑based biotech Vicebio for $1.15 billion upfront, with up to $450 million in additional milestone-dependent payments, to bolster its pipeline of non‑mRNA respiratory vaccines, including an RSV/hMPV combination candidate and access to Vicebio’s ’Molecular Clamp ‘technology that simplifies manufacturing and cold‑chain distribution.
• In April 2025, Arcturus Therapeutics Holdings Inc. announced that its self-amplifying mRNA vaccine candidate, ARCT-2304, targeting influenza A H5N1, received Fast Track Designation from the FDA, highlighting continued advancements in mRNA vaccine technology.
• In March 2024, Osivax reported that all the patients had completed the last visit of the Phase 2a clinical trial (NCT05734040). It was testing OVX836, a pan-S influenza A vaccine, as well as a quadrivalent influenza vaccine candidate (QIVs).

The Report Covers

• Market value data analysis of 2024 and forecast to 2035.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the global flu influenza vaccine market. Based on the availability of data, information related to new products and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies.
• Competitive strategies by identifying ‘who-stands-where’ in the market.

Show more